Literature DB >> 22439937

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Paolo P Provenzano1, Carlos Cuevas, Amy E Chang, Vikas K Goel, Daniel D Von Hoff, Sunil R Hingorani.   

Abstract

Pancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response. We show here that this desmoplastic reaction generates inordinately high interstitial fluid pressures (IFPs), exceeding those previously measured or theorized for solid tumors, and induces vascular collapse, while presenting substantial barriers to perfusion, diffusion, and convection of small molecule therapeutics. We identify hyaluronan, or hyaluronic acid (HA), as the primary matrix determinant of these barriers and show that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine PDA, normalize IFP, and re-expand the microvasculature. In combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22439937      PMCID: PMC3371414          DOI: 10.1016/j.ccr.2012.01.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  52 in total

Review 1.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Long-term measurement of arterial blood pressure in conscious mice.

Authors:  D L Mattson
Journal:  Am J Physiol       Date:  1998-02

Review 5.  General descriptions of passive transport of neutral solute and solvent through membranes.

Authors:  A G Ogston; C C Michel
Journal:  Prog Biophys Mol Biol       Date:  1978       Impact factor: 3.667

Review 6.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

Authors:  R M Schultz; R L Merriman; J E Toth; J E Zimmermann; L W Hertel; S L Andis; D E Dudley; P G Rutherford; L R Tanzer; G B Grindey
Journal:  Oncol Res       Date:  1993       Impact factor: 5.574

8.  Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure.

Authors:  Annica Jacobson; Alexei Salnikov; Ellen Lammerts; Pernilla Roswall; Christian Sundberg; Paraskevi Heldin; Kristofer Rubin; Nils-Erik Heldin
Journal:  Biochem Biophys Res Commun       Date:  2003-06-13       Impact factor: 3.575

9.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

Authors:  Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

10.  Interstitial hypertension in superficial metastatic melanomas in humans.

Authors:  Y Boucher; J M Kirkwood; D Opacic; M Desantis; R K Jain
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

View more
  803 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Authors:  Eric A Collisson; Christy L Trejo; Jillian M Silva; Shenda Gu; James E Korkola; Laura M Heiser; Roch-Philippe Charles; Brian A Rabinovich; Byron Hann; David Dankort; Paul T Spellman; Wayne A Phillips; Joe W Gray; Martin McMahon
Journal:  Cancer Discov       Date:  2012-05-24       Impact factor: 39.397

Review 3.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

4.  Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Authors:  Teresa S Kim; Michael J Cavnar; Noah A Cohen; Eric C Sorenson; Jonathan B Greer; Adrian M Seifert; Megan H Crawley; Benjamin L Green; Rachel Popow; Nagavarakishore Pillarsetty; Darren R Veach; Anson T Ku; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Shan Zeng; Ronald P Dematteo
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 5.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

6.  Probing cellular response to topography in three dimensions.

Authors:  Colin D Paul; Alex Hruska; Jack R Staunton; Hannah A Burr; Kathryn M Daly; Jiyun Kim; Nancy Jiang; Kandice Tanner
Journal:  Biomaterials       Date:  2019-01-08       Impact factor: 12.479

7.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

8.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

Review 9.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 10.  Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.

Authors:  Christopher J Halbrook; Marina Pasca di Magliano; Costas A Lyssiotis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-15       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.